Mankind Pharma Gears Up for Q3 Reveal on 3rd February; Check Key Expectations Here

Mankind Pharma’s Q3 results FY26 are scheduled to be announced on 3rd February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Mankind Pharma Q3 Results 2026 Preview

• Mankind Pharma’s revenue is expected to be in the range of ₹2,449.63 crore, a 0.04% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 0.72% YoY. 
• Net profit is ₹380.23 crore, up 41.81% YoY 
• EBITDA to fall 14.62%

Mankind Pharma Share Performance 

• Over the past six months, Mankind Pharma’s share price has fallen by 10.40% to ₹922.00.
• Moreover, over the past year, the stock has decreased by 89.03%.
• Despite this weak short-term performance, Mankind Pharma’s stock has delivered a financially sound 681.69% return over the past 5 years.
• As of 3rd February 2026, the stock traded at ₹922.00 per share.

Key Factors to Watch for Mankind Pharma Q3 Results FY26 

• Revenue & Volume Growth: Growth in overall sales — especially domestic formulations and chronic therapies — will indicate core demand strength as the pharma market expands.
  
• Profitability & Margins: Watch EBITDA and net profit margins to see if cost pressures (like field force and regulatory impacts) are affecting profitability.
  
• Export & Specialty Segment Performance: Performance in exports and high‑margin specialty/chronic segments (including products from the Bharat Serums & Vaccines integration) will be key for growth and margin support.
  
• New Product Approvals & R&D Impact: Updates on new launches, R&D progression, and regulatory approvals (especially for chronic, OTC, and specialty drugs) could drive future revenue momentum.
  
• Cost & Working Capital Trends: Trends in operating costs, field force efficiency, and working capital optimisation will reveal financial discipline and cash flow strength.

Final Thoughts

Mankind Pharma will announce its Q3 FY26 results on 2nd February 2026. Analysts expect 9.% YoY1.02% revenue growth, a 4.46% fall in PAT, and a 9.17% fall in EBITDA. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here